Artelo Biosciences (NASDAQ:ARTL) Stock Rating Upgraded by LADENBURG THALM/SH SH

Artelo Biosciences (NASDAQ:ARTL) was upgraded by research analysts at LADENBURG THALM/SH SH to a “strong-buy” rating in a research note issued on Wednesday,Zacks.com reports.

A number of other equities research analysts also recently issued reports on ARTL. EF Hutton Acquisition Co. I upgraded shares of Artelo Biosciences to a “strong-buy” rating in a research report on Tuesday, October 1st. D. Boral Capital reiterated a “buy” rating and set a $6.00 price objective on shares of Artelo Biosciences in a report on Monday, December 9th. Finally, HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of Artelo Biosciences in a research note on Monday, December 9th.

Artelo Biosciences Trading Up 1.4 %

NASDAQ:ARTL opened at $1.06 on Wednesday. The business’s fifty day moving average price is $1.11 and its 200 day moving average price is $1.21. The firm has a market capitalization of $3.42 million, a price-to-earnings ratio of -0.37 and a beta of 1.29. Artelo Biosciences has a 1-year low of $0.91 and a 1-year high of $1.75.

Artelo Biosciences (NASDAQ:ARTL) last issued its earnings results on Tuesday, November 12th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.06. Equities analysts forecast that Artelo Biosciences will post -2.62 earnings per share for the current year.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.